Delving into the Latest Updates on Molecule X LLC with Synapse

概览

关联

1

项与 Molecule X LLC 相关的药物

Tyrphostin AG-17

靶点-

作用机制-

在研机构-

原研机构

Molecule X LLC

在研适应症-

非在研适应症-

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 Molecule X LLC 相关的临床试验

NCT05487781

/ Unknown status早期临床1期

Phase 1 Clinical Study To Describe the Biological Safety and Pharmacokinetics of Tyrphostin AG-17 Present in Oral Solid Formulations of the Fixed Dose Combination, in Three Different Concentrations of the Compound Tyrphostin AG-17 Content 10 mg, 3.3 mg and 1 mg Respectively, With 700 mg of L-Carnitine Tartrate Each Presentation, in a Single Dose in Healthy Research Subjects of Mexican Nationality

Evaluate the biological safety and pharmacokinetics of tyrphostin AG-17 present in the solid oral formulations of the fixed-dose combination, in three different concentrations of the compound tyrphostin AG-17 contained 10 mg, 3.3 mg and 1 mg, respectively, with 700 mg of L-Carnitine tartrate each presentation, in a single dose in healthy research subjects of Mexican nationality.

开始日期2022-05-24

申办/合作机构

Molecule X LLC

100 项与 Molecule X LLC 相关的临床结果

登录后查看更多信息

0 项与 Molecule X LLC 相关的专利（医药）

登录后查看更多信息

100 项与 Molecule X LLC 相关的药物交易

登录后查看更多信息

100 项与 Molecule X LLC 相关的转化医学

登录后查看更多信息